Market Overview

UPDATE: Jefferies Downgrades Pfizer on Challenges Ahead

Related PFE
UPDATE: Protalix Shares Spike Higher on FDA Approval of Pediatric Indication for ELELYSO(TM) for Injection, for IV Use for Treatment of Type 1 Gaucher Disease
Fast Money Picks For August 28
Treasury Develolping Options to Curb Inversions (Fox Business)

In a report published Friday, Jefferies analyst Jeffrey Holford downgraded the rating on Pfizer (NYSE: PFE) from Buy to Hold, and lowered the price target from $32.00 to $30.00.

In the report, Jefferies noted, “Rising rate expectations had the expected impact on the sector, which has been driven by income investors over the past two years. Q2'13 earnings look tough in this context and we expect most companies to see some pressure. Novartis, Sanofi, Roche, Abbott, AbbVie and Bayer remain high conviction Buy ideas. We have downgraded Bristol-Myers and Pfizer to Hold in this report as part of our update today.”

Pfizer closed on Thursday at $28.44.

Posted-In: Jefferies Jeffrey HolfordAnalyst Color Downgrades Analyst Ratings

 

Related Articles (PFE)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters